InvestSMART

CSL Limited (ASX: CSL) - Announcements

- Current share price for CSL : $201.680

ASX company news and announcements for CSL Limited (CSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All CSL Limited (CSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than CSL Limited (CSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for CSL Limited (CSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$96,865 CSL announces on-market share buyback 9 Jun 2009 8:32AM $30.490 $201.850 risen by 562.02%
$96,865 CSL and Talecris agree to terminate Merger Agreement 9 Jun 2009 8:32AM $30.490 $201.850 risen by 562.02%
$96,865 CSL Receives Order from U.S,. Government for H1N1 Vaccine 29 May 2009 8:27AM $29.200 $201.850 risen by 591.27%
$96,865 Confirms commitment to Talecris acquisition 28 May 2009 9:37AM $29.030 $201.850 risen by 595.32%
$96,865 Proposed Acquisition of Talecris 7 May 2009 10:38AM $31.910 $201.850 risen by 532.56%
$96,865 Half Yearly Report and Accounts 18 Feb 2009 8:27AM $36.830 $201.850 risen by 448.06%
$96,865 CSL receives FTC request on proposed merger with Talecris 13 Oct 2008 9:34AM $38.190 $201.850 risen by 428.54%
$96,865 Completes institutional equity raising 14 Aug 2008 2:01PM $37.650 $201.850 risen by 436.12%
$96,865 Preliminary Final Report Accounts and Media Release 13 Aug 2008 9:14AM $36.900 $201.850 risen by 447.02%
$96,865 CSL announces agreement to acquire Talecris 13 Aug 2008 9:14AM n/a $201.850 n/a
$96,865 Trading Halt 13 Aug 2008 8:43AM n/a $201.850 n/a
$96,865 CSL Half Yearly Report and Half Year Accounts 20 Feb 2008 8:54AM $37.200 $201.850 risen by 442.61%
$96,865 Unsolicited share offers 14 Feb 2008 3:44PM $32.050 $201.850 risen by 529.80%
$96,865 Current ASX Code 19 Oct 2007 4:34PM $33.900 $201.850 risen by 495.43%
$96,865 Proposed 3 for 1 Share Split 17 Oct 2007 2:11PM $34.320 $201.850 risen by 488.14%
$96,865 US FDA approves Afluria 1 Oct 2007 8:57AM $107.800 $201.850 risen by 87.24%
$96,865 Appendix 3C 22 Aug 2007 8:30AM $96.400 $201.850 risen by 109.39%
$96,865 Preliminary Final Report Accounts and Media Release 22 Aug 2007 8:29AM $96.400 $201.850 risen by 109.39%
$96,865 Approval of Privigen 27 Jul 2007 9:45AM n/a $201.850 n/a
$96,865 Gardasil Cross Protection Data 18 Apr 2007 9:59AM $84.200 $201.850 risen by 139.73%
$96,865 Half Yearly Report/Half Year Accounts 21 Feb 2007 8:27AM $77.420 $201.850 risen by 160.72%
$96,865 Secures long term supply of Helixate from Bayer 2 Feb 2007 8:59AM $70.500 $201.850 risen by 186.31%
$96,865 Strong trading conditions in international plasma therapies 13 Dec 2006 9:30AM $62.750 $201.850 risen by 221.67%
$96,865 Welcomes Federal Government Decision on Gardasil 29 Nov 2006 11:37AM $59.000 $201.850 risen by 242.12%
$96,865 Zenyth Option Scheme of Arrangement approved by Court 17 Nov 2006 4:10PM $58.070 $201.850 risen by 247.60%

1151 - 1175 of 1206 results

Page 47 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.